Atrial Fibrillation and Heart Failure

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide and has a strong association with heart failure (HF). It often remains unclear if HF is the cause or consequence of AF due to the complexity of the processes that are involved in both the perpetuation of AF and the development of HF. To date, two therapeutic strategies are accepted as the standard of care in AF patients with heart failure. Rhythm control aims to permanently restore sinus rhythm, whereas a rate-control strategy aims to slow ventricular rate without the termination of AF. In the last 5 years a tremendous number of important studies have been published investigating the optimal therapeutic strategy in HF patients. This review highlights the important studies with respect to the involvement of AF in promoting left-ventricular dysfunction and discusses the optimal strategy in HF patients suffering from AF.

[1]  J. Healey,et al.  Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial , 2022, Circulation.

[2]  K. Addetia,et al.  Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation. , 2022, Journal of the American College of Cardiology.

[3]  I. V. Van Gelder,et al.  AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. , 2021, European heart journal.

[4]  G. Breithardt,et al.  Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure , 2021, Circulation.

[5]  L. Di Biase,et al.  Amiodarone is associated with increased short-term mortality in elderly atrial fibrillation patients with preserved ejection fraction , 2021, Journal of Interventional Cardiac Electrophysiology.

[6]  E. Kholmovski,et al.  Efficacy of LGE‐MRI‐guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design , 2021, Journal of cardiovascular electrophysiology.

[7]  D. Mark,et al.  Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure , 2021, Circulation.

[8]  J. Gummert,et al.  Catheter ablation for atrial fibrillation in patients with end‐stage heart failure and eligibility for heart transplantation , 2020, ESC heart failure.

[9]  Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[10]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[11]  G. Breithardt,et al.  Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. , 2020, The New England journal of medicine.

[12]  K. Chun,et al.  Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. , 2020, European heart journal.

[13]  T. Potpara,et al.  The role of amiodarone in contemporary management of complex cardiac arrhythmias. , 2019, Pharmacological research.

[14]  N. Marrouche,et al.  Atrial fibrillation and cardiac fibrosis. , 2019, European heart journal.

[15]  D. Scherr,et al.  Effects of Atrial Fibrillation on the Human Ventricle , 2019, Circulation research.

[16]  S. Prabhu,et al.  Atrial Remodeling Following Catheter Ablation for Atrial Fibrillation-Mediated Cardiomyopathy: Long-Term Follow-Up of CAMERA-MRI Study. , 2019, JACC. Clinical electrophysiology.

[17]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[18]  G. Hasenfuss,et al.  Reverse left ventricular structural remodeling after catheter ablation of atrial fibrillation in patients with preserved left ventricular function: Insights from cardiovascular magnetic resonance native T1 mapping. , 2019, Heart rhythm.

[19]  S. Prabhu,et al.  Regression of Diffuse Ventricular Fibrosis Following Restoration of Sinus Rhythm With Catheter Ablation in Patients With Atrial Fibrillation and Systolic Dysfunction: A Substudy of the CAMERA MRI Trial. , 2018, JACC. Clinical electrophysiology.

[20]  S. Prabhu,et al.  Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. , 2017, Journal of the American College of Cardiology.

[21]  A. Rigby,et al.  Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. , 2017, Journal of the American College of Cardiology.

[22]  J. Jalife,et al.  Atrial remodeling, fibrosis, and atrial fibrillation. , 2015, Trends in cardiovascular medicine.

[23]  Nazem Akoum,et al.  Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. , 2014, JAMA.

[24]  M. O'Neill,et al.  Catheter ablation of atrial fibrillation in heart failure. , 2013, Heart failure clinics.

[25]  A. Baranchuk,et al.  Atrial Failure as a Clinical Entity , 2020 .